1. Context
2. Methods
2.1. Literature Search and Study Selection
2.2. Eligibility Criteria
2.3. Study Screening and Data Extraction
2.4. Quality of Assessment and Risk of Bias
2.5. Statistical Analysis
3. Results
3.1. Study Selection and Characteristic
| Main Author (Year) | Country | Sample Size | Male: Female | Age, Mean ± SD | Duration of Pain, mo | Measurement of Clinical Outcomes | Level of Dominant HNP | Previous Pain Score, Mean ± SD | Quality of the Study (OCEBM) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRF Group | Control Group | PRF Group | Control Group | PRF Group | Control Group | |||||||
| Simopoulos et al. (2008) (7) | United States of America | 76 | 45:31 | 39 | 55.1 ± 14.3 | 53.8 ± 14 | > 6 | VAS | L5-S1 | 7.8 ± 1,6 | 7,1 ± 1,9 | 2 |
| Koh et al. (2012) (8) | South Korea | 62 | 11:20 | 10:21 | 65.97 ± 7.25 | 65.16 ± 8.96 | ≥ 3 | NRS; ODI | L5 | 7.39 ± 0.37 | 7.00 ± 0.43 | 2 |
| Shanthanna et al. (2014) (9) | Canada | 31 | 10:6 | 8:7 | 57 (35 - 83) | 57 (35 - 83) | ≥ 4 | VAS | L5-S1 | not reported | not reported | 2 |
| Lee et al. (2015) (6) | South Korea | 18 | Not reported | Not reported | 54.3 ± 12.1 | 50.8 ± 12.7 | 5 | VAS; ODI | L5-S1 | 5.3 ± 1.2 | 4.9 ± 0.8 | 2 |
| Khalifa and Saadalla (2017) (10) | Egypt | 90 | 59:31 | 45 | 37.5 ± 9 | 39.3 ± 8.8 | > 3 | VAS | L5-S1 | 7.53 ± 0.5 | 7.5 ± 0.5 | 2 |
| De et al. (2018) (11) | India | 50 | 9:16 | 13:12 | 41.92 ± 14.53 | 41.4 ± 10.64 | > 3 | VAS; ODI | L5-S1 | 8.24 ± 0.96 | 8.12 ± 1.05 | 2 |
Abbreviations: ODI, Oswestry disability index; Oxford Center for Evidence-Based Medicine; SD, standard deviation; OCEBM, VAS, Visual Analog scale.
| Author (Year) | Therapeutic Target | Intervention Parameter | Control Group | Follow up | Result | Adverse Effect | Result of the Study | Limitation | |
|---|---|---|---|---|---|---|---|---|---|
| Pain | Functional | ||||||||
| Simopoulos et al. (2008) (7) | DRG | 42°C, 120 seconds | PRF + CRF | Eight weeks; eight months | Significant compared to the control group | not reported | not reported | 70% of the PRF group patients and 82% of the PRF + CRF group patients had a reduced pain intensity in the second month. The analgesic response was 3.18 months (± 2.81) in the PRF group and 4.39 months (± 3.50) in the PRF + CRF group. The chances of success for both groups were close to 50% in the third month. After eight months, most of the patients experienced no improvement in pain. There were no statistical differences between the PRF group and the PRF + CRF group. | Short-term evaluations were not reported; side effects were not reported. |
| Koh et al. (2012) (8) | DRG | 42°C, 120 seconds | Sham (needle placement) | Four weeks; eight weeks; 12 weeks | Significant compared to the control group | Not Significant compared to the control group | No side effect | The number of patients with successful treatment outcomes was higher in the PRF group in the second (P = 0.032) and third months (P = 0.018). No significant differences were observed regarding the secondary outcome variable (ODI) between the two groups. | Long-term evaluations were not reported. |
| Shanthanna et al. (2014) (9) | DRG | 42°C, 120 seconds | Sham (needle placement) | 24 hours; one week; Four weeks; eight weeks; 12 weeks | Not Significant compared to the control group | Not Significant compared to the control group | No side effect | The differences in VAS and ODI reduction in the PRF groups were not significant in the fourth week and the third month compared to the placebo (oral analgesic drug). Six out of 16 subjects in the PRF group and three out of 15 subjects in the control group experienced a VAS reduction of > 50%. There were no PRF side effects. | Small sample size; no initial VAS data was included; long term evaluation was not reported. |
| Lee et al. (2015) (6) | DRG | 42°C, 240 seconds | TFESI (dexamethasone 5 mg | Two weeks; Four weeks; eight weeks; 12 weeks | Not Significant compared to the control group | Not Significant compared to the control group | increasing of radicular pain (n = 1) | The difference in VAS reduction, ODI in the PRF group was not statistically significant compared to the control group (TFESI of dexamethasone 5 mg) | Small sample size; low baseline VAS; long term evaluations were not reported. |
| Khalifa and Saadalla (2017) (10) | DRG | 42°C, 120 seconds | TFESI (methylprednisolone 2 mg) | One week; Four weeks; eight weeks; 12 weeks | Significant compared to the control group | Significant compared to control group | not reported | The difference in VAS reduction, ODI (dorsal lumbar root ganglion) was more significant in the PRF group than in the control group (transforaminal epidural injection of methylprednisolone steroid 24 mg) up to three months of follow-up in lumbar HNP patients. | Long-term evaluations were not reported; side effects were not reported |
| Mohan et al. (2018) (11) | DRG | 42°C, 180 seconds | TFESI | Two weeks; Four weeks; Eight weeks; 12 weeks; 24 weeks | Significant compared to the control group | Significant compared to control group | not reported | The difference in VAS reduction, ODI (dorsal lumbar root ganglion) was more significant in the PRF group than in the control group (TFESI injection) up to 24- week evaluation. | Long-term evaluations were not reported; side effects were not reported. |
Abbreviations: CRF, continuous radiofrequency; DRG, dorsal root ganglion; TFESI, transforaminal epidural steroid injection.




